A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
NCT04617275 on ClinicalTrials.gov · last registry update 2022-12-08
Finished 17 November 2021, after enrolling 151 people. Primary outcome, as filed: Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity. danuglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- danuglipron
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Enrollment
- 151
- Started
- 2021-01-06
- Primary completion
- 2021-11-17 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
Conditions studied
Diabetes · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the danuglipron page for this molecule’s full trial and approval history.